ENTITY
Dr. Reddy's Laboratories

Dr. Reddy's Laboratories (DRRD IN)

252
Analysis
Health Care • India
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that researches, develops, manufactures, and markets a wide array of pharmaceutical products and services. The company produces over 190 medications, 60 active pharmaceutical ingredients, diagnostic kits, critical care, and biotechnology products. It operates globally across multiple regions, offering generic drugs, active pharmaceutical ingredients (APIs), differentiated formulations, biosimilars, and proprietary products. The company was founded in 1984 and is headquartered in Hyderabad, Telangana, India.
more
•04 Feb 2026 09:17•Broker

Impact of India-US Trade Deal

The US has decided to reduce the reciprocal tariff on Indian goods to 18% from the earlier 50%. The trade deal is structurally positive for India’s...

Logo
133 Views
Share
•04 Feb 2026 08:11•Broker

Impact of India-US Trade Deal

The US has decided to reduce the reciprocal tariff on Indian goods to 18% from the earlier 50%. The trade deal is structurally positive for India’s...

Logo
157 Views
Share
•26 Jan 2026 10:25•Broker

HSIE Results Daily: Dr Reddy’s Laboratories, Supreme Industries, Dalmia Bharat, Gujarat Gas...

Dr Reddy’s Laboratories: EBITDA^ declined 11% YoY due to moderate sales growth of +4% YoY (as 10% QoQ decline in the US on lower gRevlimid sales...

Logo
163 Views
Share
•23 Jan 2026 09:04•Broker

HSIE Results Daily: Dr Reddy’s Laboratories, Supreme Industries, Dalmia Bharat...

Dr Reddy’s Laboratories: EBITDA^ declined 11% YoY due to moderate sales growth of +4% YoY (as 10% QoQ decline in the US on lower gRevlimid sales...

Logo
192 Views
Share
•18 Jan 2026 08:30

APAC Healthcare Weekly (January 18) – ImmuneOnco, Wuxi Bio, Eisai, Daiichi, SK Biopharm, HK Inno.N

ImmuneOnco got trial approval for atherosclerosis drug candidate, timdarpacept in China. Eisai secures rights to NSCLC drug taletrectinib. HK inno...

Logo
411 Views
Share
x